Proton Pump Inhibitors and DAPT
The use of proton pump inhibitors (PPIs) in patients treated with DAPT (Dual Antiplatelet Therapy ) is discussed in a 2010 ACCF/ACG/AHA expert consensus document . Recommendations on the use of PPIs are given in the 2011 ACCF/AHA/SCAI PCI guideline. PPIs should be used in patients with a history of prior gastrointestinal bleeding treated with DAPT (Class I). In patients with increased risk of gastrointestinal bleeding, including those with advanced age and those with concomitant use of warfarin, steroids, or nonsteroidal anti-inflammatory drugs, use of PPIs is reasonable (Class IIa). Routine use of PPIs is not recommended for patients at low risk of gastrointestinal bleeding (Class III: No Benefit).